osteoarthritis Archives

L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis

June 1, 2026 By BioInformant Team Leave a Comment

Innovative Participant-Funded Study Harnesses Enhanced Autologous Adipose-Derived Stem Cells to Combat Degenerative Joint Disease

ESCAZU, COSTA RICA, June 1, 2026 — L2 Bio, LLC has formally announced the launch of the C-ROW Site Beta (C-ROW), an innovative, participant-funded research project based in Costa Rica welcoming the safety and convenience of utilizing local participation of your USA or Canadian based doctor. The study centers on the use of enhanced autologous adipose-derived stem cells (ADSCs) to address the debilitating progression of osteoarthritis. [Read more…]

Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study

October 9, 2025 By BioInformant Team Leave a Comment

The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of XSTEM. Xintela has previously communicated positive interim results up to 18 months after treatment of knee osteoarthritis patients with three dose levels of XSTEM. The highest dose level, which showed the best results after 18 months, has now shown sustained positive treatment effects two years after XSTEM treatment.

XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. [Read more…]

Exploring Alternative Treatments for Alleviating Pain from Osteoarthritis

December 11, 2023 By BioInformant Team Leave a Comment

As the years pass, our bodies take on many changes. Some we can control and others, like Osteoarthritis (OA), are a little more out of our hands – but that doesn’t mean you have to let it control you! In this article, we will explore the connection between aging and OA, what causes it, how to manage your symptoms effectively so that you can age gracefully with an active lifestyle. So if you’re ready to get proactive about your health as you age and learn how to best manage the effects of osteoarthritis in your life, then stay tuned for some exciting tips. [Read more…]

Dubai First to Launch Innovative Stem Cell Therapy for Joint Disease

November 21, 2017 By Cade Hildreth, Founder & President Leave a Comment

UAE residents will no longer need to travel abroad to receive stem cell therapy for joint disease

Dubai, United Arab Emirates, November 21 2017 – Bioscience Clinic FZ LLC located in Dubai Healthcare City is pleased to launch to its latest innovative stem cells therapy for treatment of joint disease. Established since 2012, Bioscience Clinic is Dubai’s first and most advanced clinic to use stem cells taken from adipose tissue in a variety of clinical applications. Its latest therapy was first introduced in Europe by Bioscience Institute, a Bioscience Clinic sister company. [Read more…]

Regeneus and AGC Asahi Glass Partner to Develop Progenza in Japan

December 29, 2016 By Cade Hildreth, Founder & President Leave a Comment

Key Points

Regeneus collaborates with AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals, for exclusive manufacture of Progenza stem cell technology for Japanese market
Regeneus to receive US$16.5m with $5.5m upfront and US$11m in specified milestone payments
Regeneus and AGC establish 50/50 joint venture for exclusive clinical development and commercialisation of Progenza for osteoarthritis and all inflammatory conditions for Japanese market
AGC to expand its leading biopharma manufacturing business into regenerative medicine products

Sydney, Australia – 29 December 2016 – Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals, for the manufacture, clinical development and commercialisation of Progenza, a patented off-the-shelf stem cell technology platform, for the Japanese market.

[Read more…]